CLINICAL RESEARCH: HEART FAILURE
Clinical Effectiveness of Beta-Blockers in Heart FailureFindings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry
Adrian F. Hernandez, MD, MHS*, ,*,
Bradley G. Hammill, MS*,
Christopher M. O'Connor, MD, FACC*,,
Kevin A. Schulman, MD*,,
Lesley H. Curtis, PhD*, and
Gregg C. Fonarow, MD, FACC
* Duke Clinical Research Institute, Durham, North Carolina
Department of Medicine, Duke University School of Medicine, Durham, North Carolina
Ahmanson-UCLA Cardiomyopathy Center, Department of Medicine, UCLA Medical Center, Los Angeles, California
Manuscript received April 25, 2008;
revised manuscript received August 25, 2008,
accepted September 22, 2008.
* Reprint requests and correspondence: Dr. Adrian F. Hernandez, Duke Clinical Research Institute, P.O. Box 17969, Durham, North Carolina 27715 (Email: adrian.hernandez{at}duke.edu).
Objectives: We sought to examine associations between initiation of beta-blocker therapy and outcomes among elderly patients hospitalized for heart failure.
Background: Beta-blockers are guideline-recommended therapy for heart failure, but their clinical effectiveness is not well understood, especially in elderly patients.
Methods: We merged Medicare claims data with OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) records to examine long-term outcomes of eligible patients newly initiated on beta-blocker therapy. We used inverse probability–weighted Cox proportional hazards models to determine the relationships among treatment and mortality, rehospitalization, and a combined mortality–rehospitalization end point.
Results: Observed 1-year mortality was 33%, and all-cause rehospitalization was 64%. Among 7,154 patients hospitalized with heart failure and eligible for beta-blockers, 3,421 (49%) were newly initiated on beta-blocker therapy. Among patients with left ventricular systolic dysfunction (LVSD) (n = 3,001), beta-blockers were associated with adjusted hazard ratios of 0.77 (95% confidence interval [CI]: 0.68 to 0.87) for mortality, 0.89 (95% CI: 0.80 to 0.99) for rehospitalization, and 0.87 (95% CI: 0.79 to 0.96) for mortality–rehospitalization. Among patients with preserved systolic function (n = 4,153), beta-blockers were associated with adjusted hazard ratios of 0.94 (95% CI: 0.84 to 1.07) for mortality, 0.98 (95% CI: 0.90 to 1.06) for rehospitalization, and 0.98 (95% CI: 0.91 to 1.06) for mortality–rehospitalization.
Conclusions: In elderly patients hospitalized with heart failure and LVSD, incident beta-blocker use was clinically effective and independently associated with lower risks of death and rehospitalization. Patients with preserved systolic function had poor outcomes, and beta-blockers did not significantly influence the mortality and rehospitalization risks for these patients.
Key Words: adrenergic beta-antagonists • heart failure • mortality patient readmission
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ARB = angiotensin receptor blocker | | CI = confidence interval | | LVEF = left ventricular ejection fraction | | LVSD = left ventricular systolic dysfunction |
|
Related Articles
-
Beta-Blockers in Elderly Patients With Heart Failure: Ready for Prime Time?
- Mitja Lainscak, Hans-Dirk Duengen, and Stefan D. Anker
J. Am. Coll. Cardiol. 2009 54: 2202.
[Full Text]
[PDF]
-
Stainless Steel Stents and Magnetic Resonance Imaging: Looking Into a Black Hole
- Damien Kenny, Mark C.K. Hamilton, and Robin P. Martin
J. Am. Coll. Cardiol. 2009 54: 2202-2203.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2009 53: A24.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Albaghdadi, M. Gheorghiade, and B. Pitt
Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes
Eur. Heart J.,
November 1, 2011;
32(21):
2626 - 2633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Guazzi, M. Vicenzi, R. Arena, and M. D. Guazzi
Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study
Circulation,
July 12, 2011;
124(2):
164 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. O. Oghlakian, I. Sipahi, and J. C. Fang
Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm?
Mayo Clin. Proc.,
June 1, 2011;
86(6):
531 - 539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Bufalino, F. A. Masoudi, S. K. Stranne, K. Horton, N. M. Albert, C. Beam, R. O. Bonow, R. L. Davenport, M. Girgus, G. C. Fonarow, et al.
The American Heart Association's Recommendations for Expanding the Applications of Existing and Future Clinical Registries: A Policy Statement From the American Heart Association
Circulation,
May 17, 2011;
123(19):
2167 - 2179.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Borlaug and M. M. Redfield
Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum
Circulation,
May 10, 2011;
123(18):
2006 - 2014.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Holland, D. J. Kumbhani, S. H. Ahmed, and T. H. Marwick
Effects of Treatment on Exercise Tolerance, Cardiac Function, and Mortality in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
J. Am. Coll. Cardiol.,
April 19, 2011;
57(16):
1676 - 1686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Borlaug and W. J. Paulus
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Eur. Heart J.,
March 2, 2011;
32(6):
670 - 679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-J. Kwon, D.-B. Kim, S.-W. Jang, K.-D. Yoo, K.-W. Moon, B. J. Shim, S.-H. Ahn, E.-J. Cho, T.-H. Rho, and J.-H. Kim
Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease
Eur J Heart Fail,
December 1, 2010;
12(12):
1339 - 1344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Iqbal, L. Francis, J. Reid, S. Murray, and M. Denvir
Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality
Eur J Heart Fail,
September 1, 2010;
12(9):
1002 - 1008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Paulus and J. J.M. van Ballegoij
Treatment of Heart Failure With Normal Ejection Fraction: An Inconvenient Truth!
J. Am. Coll. Cardiol.,
February 9, 2010;
55(6):
526 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. V. Ramani, P. A. Uber, and M. R. Mehra
Chronic Heart Failure: Contemporary Diagnosis and Management
Mayo Clin. Proc.,
February 1, 2010;
85(2):
180 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lainscak, H.-D. Duengen, and S. D. Anker
Beta-Blockers in Elderly Patients With Heart Failure: Ready for Prime Time?
J. Am. Coll. Cardiol.,
December 1, 2009;
54(23):
2202 - 2202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tschope and W. J. Paulus
Doppler Echocardiography Yields Dubious Estimates of Left Ventricular Diastolic Pressures
Circulation,
September 1, 2009;
120(9):
810 - 820.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, A. Torabi, and A. L. Clark
Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF
Eur J Heart Fail,
August 1, 2009;
11(8):
802 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kramer, L. H. Curtis, C. S. Dupree, A. F. Hernandez, M. Massing, and K. J. Anstrom
Eligibility Criteria for {beta}-Blockade Might Have to Be Taken Into Account--Reply
Arch Intern Med,
June 8, 2009;
169(11):
1078 - 1078.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. P. Jolobe
Eligibility Criteria for {beta}-Blockade Might Have to Be Taken Into Account
Arch Intern Med,
June 8, 2009;
169(11):
1077 - 1078.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Tardif
Heart rate as a treatable cardiovascular risk factor
Br. Med. Bull.,
June 1, 2009;
90(1):
71 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Hernandez and G. C. Fonarow
BNP-Guided Heart Failure Therapy in Older Patients
JAMA,
May 27, 2009;
301(20):
2091 - 2092.
[Full Text]
[PDF]
|
|
|
|
